Skip to main content
. 2018 Jun 29;67(9):1847–1857. doi: 10.2337/db17-1513

Figure 1.

Figure 1

Erlotinib effectively inhibited EGFR tyrosine kinase activity in eNOS−/−db/db mice. A: Erlotinib inhibited the levels of phosphorylated EGFR (p-EGFR) at different tyrosine residues. B: Erlotinib treatment led to decreased levels of phosphorylated extracellular signal–regulated kinase (p-ERK), a downstream signaling target of EGFR activation.